Journal of Ovarian Research

Papers
(The H4-Index of Journal of Ovarian Research is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis220
The prolactin receptor gene (PRLR) is linked and associated with the risk of polycystic ovarian syndrome180
Correction: Metformin modifies plasma microbial-derived extracellular vesicles in polycystic ovary syndrome with insulin resistance91
Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report83
Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer67
Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study63
Investigating the potential causal link between BPA and ovarian carcinogenesis: a network toxicology and mendelian randomization study on the CTRC/PRDX1/SKP1 pathway57
Protective effect of Luffa cylindrica fermentation liquid on cyclophosphamide-induced premature ovarian failure in female mice by attenuating oxidative stress, inflammation and apoptosis56
Serum LH levels before progesterone administration significantly affect pregnancy outcomes in hormone replacement therapy-frozen-thawed embryo transfer cycles56
Improved clinical outcomes with a modified warming protocol in donor oocyte cycles49
Smooth endoplasmic reticulum aggregates in oocytes: a comparison of progestin-primed and GnRH antagonist IVF protocols48
Integrated multi-omics analysis identifies TLR4-mediated mechanisms in ATBC-induced ovarian dysfunction and female infertility: A network toxicology, transcriptomic, and Mendelian randomization study48
Comparison of oocyte vitrification using a semi-automated or a manual closed system in human siblings: survival and transcriptomic analyses46
Evaluation of calcification distribution by CT-based textural analysis for discrimination of immature teratoma44
Generation of healthy bovine ovarian organoids: a proof-of-concept derivation technique42
Effects of vitrified cryopreservation duration on IVF and neonatal outcomes39
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis38
HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer38
Ginseng alleviates folliculogenesis disorders via induction of cell proliferation and downregulation of apoptotic markers in nicotine-treated mice36
The presence of ovarian endometrioma adversely affect ovarian reserve and response to stimulation but not oocyte quality or IVF/ICSI outcomes: a retrospective cohort study36
Long noncoding RNA SNHG25 promotes the malignancy of endometrial cancer by sponging microRNA-497-5p and increasing FASN expression33
Causal relationship between inflammatory cytokines and polycystic ovary syndrome: a bidirectional mendelian randomization study31
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy31
Expression of long noncoding RNAs in the ovarian granulosa cells of women with diminished ovarian reserve using high-throughput sequencing31
Laser-assisted hatching is associated with reduced re-expansion of vitrified-thawed blastocysts and has no significant effect on embryo implantation30
Comprehensive in silico analysis of prognostic and immune infiltrates for FGFs in human ovarian cancer29
The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells29
In vitro drug testing using patient-derived ovarian cancer organoids29
Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient29
0.062489986419678